© 2005 Oxford University Press
ARTICLE |
A Large Cohort Study of Aspirin and Other Nonsteroidal Anti-inflammatory Drugs and Prostate Cancer Incidence
Affiliation of authors: Epidemiology and Surveillance Research, American Cancer Society, National Home Office, Atlanta, GA
Correspondence to: Eric J. Jacobs, PhD, Epidemiology and Surveillance Research, American Cancer Society, National Home Office, 1599 Clifton Rd., NE, Atlanta, GA 30329 (e-mail: eric.jacobs{at}cancer.org).
Background: Use of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) has consistently been associated with a reduced risk of colon cancer. Recent epidemiologic studies have suggested that the use of NSAIDs, particularly aspirin, may also be associated with a reduced risk of prostate cancer, but the evidence remains limited. Methods: We examined the association between NSAID use and prostate cancer incidence among 70 144 men in the American Cancer Society's Cancer Prevention Study II Nutrition Cohort. Information on NSAID use was obtained from a questionnaire completed at study enrollment in 1992–1993 and was updated using follow-up questionnaires in 1997 and 1999. We calculated rate ratios (RRs) and 95% confidence intervals (CIs) for prostate cancer incidence associated with NSAID use, adjusting for age and potential prostate cancer risk factors. Results: During follow-up from 1992–1993 through August 31, 2001, 4853 cases of incident prostate cancer were identified. Neither current aspirin use nor current use of NSAIDs (aspirin and other NSAIDs combined) was associated with prostate cancer risk, even at the highest usage level (60 or more pills per month). However, long-duration regular use (30 or more pills per month for 5 or more years) of NSAIDs was associated with reduced risk of prostate cancer (RR = 0.82, 95% CI = 0.71 to 0.94). Long-duration regular use of aspirin was also associated with reduced risk of prostate cancer (RR = 0.85, 95% CI = 0.73 to 0.99). The absolute rate of prostate cancer (standardized to the age distribution of study participants using 5-year age categories) was 1013 per 100 000 person-years among men who had never reported NSAID use, and 847 per 100 000 person-years among long duration regular NSAID users. Conclusions: These results support the hypothesis that long duration regular NSAID use is associated with modestly reduced risk of prostate cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
Find additional patient-related information at:
This article has been cited by other articles:
|
|
 |
|
  T. J. Murtola, T. L. J. Tammela, J. Lahtela, and A. Auvinen Antidiabetic Medication and Prostate Cancer Risk: A Population-based Case-Control Study Am. J. Epidemiol., August 11, 2008; (2008) kwn190v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Asgari, S. S. Maruti, and E. White A Large Cohort Study of Nonsteroidal Anti-inflammatory Drug Use and Melanoma Incidence J Natl Cancer Inst, July 2, 2008; 100(13): 967 - 971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Flick, L. A. Habel, K. A. Chan, S. K. Van Den Eeden, V. P. Quinn, R. Haque, E. J. Orav, J. D. Seeger, M. C. Sadler, C. P. Quesenberry Jr., et al. Statin Use and Risk of Prostate Cancer in the California Men's Health Study Cohort Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2218 - 2225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bardia, J. O. Ebbert, R. A. Vierkant, P. J. Limburg, K. Anderson, A. H. Wang, J. E. Olson, C. M. Vachon, and J. R. Cerhan Association of Aspirin and Nonaspirin Nonsteroidal Anti-inflammatory Drugs With Cancer Incidence and Mortality J Natl Cancer Inst, June 6, 2007; 99(11): 881 - 889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Jacobs, M. J. Thun, E. B. Bain, C. Rodriguez, S. J. Henley, and E. E. Calle A Large Cohort Study of Long-Term Daily Use of Adult-Strength Aspirin and Cancer Incidence J Natl Cancer Inst, April 18, 2007; 99(8): 608 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Cheng, S. J. Plummer, G. Casey, and J. S. Witte Toll-Like Receptor 4 Genetic Variation and Advanced Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 352 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Liu, S. J. Plummer, N. L. Nock, G. Casey, and J. S. Witte Nonsteroidal Antiinflammatory Drugs and Decreased Risk of Advanced Prostate Cancer: Modification by Lymphotoxin Alpha Am. J. Epidemiol., November 15, 2006; 164(10): 984 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J O'Loughlin, E Dugas, K Maximova, and N Kishchuk Reporting of ethnicity in research on chronic disease: update Postgrad. Med. J., November 1, 2006; 82(973): 737 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. K. Yiu and A. Toker NFAT Induces Breast Cancer Cell Invasion by Promoting the Induction of Cyclooxygenase-2 J. Biol. Chem., May 5, 2006; 281(18): 12210 - 12217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. Garcia, H.-G. Wisniewski, M. S. Lucia, N. Arevalo, T. J. Slaga, S. L. Kraft, R. Strange, and A. P. Kumar 2-Methoxyestradiol Inhibits Prostate Tumor Development in Transgenic Adenocarcinoma of Mouse Prostate: Role of Tumor Necrosis Factor-{alpha}-Stimulated Gene 6 Clin. Cancer Res., February 1, 2006; 12(3): 980 - 988. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Okayama, Y. Hamanaka, Y. Suehiro, Y. Hasui, J. Nakamura, and Y. Hinoda Association of Interleukin-10 Promoter Single Nucleotide Polymorphisms -819 T/C and -592 A/C With Aging J. Gerontol. A Biol. Sci. Med. Sci., December 1, 2005; 60(12): 1525 - 1529. [Abstract] [Full Text] [PDF]
|
|